Novavax shares jump as FDA panel backs COVID vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up on AI enthusiasm, Mideast negotiation hopes
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices drop about 3% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- S&P 500 ends marginally lower as investors focus on US-Iran war
Novavax's (NVAX) Covid-19 Vaccine Approval in the U.S. Could Be Delayed - CNBC
June 9, 2022 10:16 AM EDTThe U.S. Food and Drug Administration's (FDA) decision on Novavax's (NASDAQ: NVAX) Covid-19 vaccine could be delayed, according to a report by CNBC.
An FDA spokesperson told CNBC that the regulatory body will have to review modifications to the drugmakers... More
